Palavras-chave
Insuficiencia cardíaca
Calidad de vida
Estudios de validación.
Calidad de vida
Estudios de validación.
Como Citar
Rojas, L. Z., Hernández, J. A., Trujillo caceres, S. J., Roa, Z. M., Jurado, A. M., Echeverría, L. E., Muka, T., & Franco, O. H. (2018). Propiedades psicométricas del “Minnesota Living with Chronic Heart Failure Questionnaire” en una Población Colombiana. Salud UIS, 51(1), 11–22. https://doi.org/10.18273/revsal.v51n1-2019002
Resumo
Introducción: El Minnesota Living with Heart Failure Questionnaire (MLHF-Q) es uno de los instrumentos más utilizados para medir la Calidad de Vida Relacionada con la Salud (CVRS) en pacientes con Falla cardíaca Crónica (FCC); sin embargo, éste no ha sido validado en poblaciones latinoamericanas hispanohablantes. Objetivo: Evaluar la consistencia interna y validez de constructo del MLHF-Q en pacientes con FCC de Colombia. Métodos: La versión en español del MLHF-Q fue diligenciada por 200 pacientes. La consistencia interna se evaluó con el Alpha de Cronbach. La validez de constructo fue examinada por dos métodos: Análisis de Componentes Principales (ACP) confirmatorio y análisis Rasch. Se evaluó la capacidad discriminativa del instrumento con la prueba U-Mann-Whitney. Resultados: Mediana de edad de 64 años, 63% hombres y el 79.5% de los participantes tenían fracción de eyección del ventrículo izquierdo (FEVI) ≤ 45%. La mediana del puntaje total de CVRS fue 40 puntos (Q1=20; Q3=55), dimensión física 11 puntos (Q1=4; Q3=23) y dimensión emocional 7 puntos (Q1=3; Q3=13). La consistencia interna fue 0.91 (IC 95% 0.89 - 0.93). En el ACP, las tres dimensiones explicaron el 54.0% y 47.7% en el análisis Rasch, en éste último cinco ítems presentaron desajuste. Se observó peor CVRS en mujeres que en hombres en la dimensión emocional (p=0.047) y se evidenció capacidad discriminativa de las subescalas y el puntaje total del MLHF-Q en la edad y la clase funcional New York Heart Association (NYHA) (p<0.05). Conclusión: Nuestros hallazgos confirmaron la estructura de tres factores del MLHF-Q y un nivel satisfactorio para la consistencia interna. Adicionalmente, estos resultados sugieren que el cuestionario refleja adecuadamente la gravedad de la enfermedad. Sin embargo, se requieren estudios adicionales en población colombiana para validar estos hallazgos y evaluar la sensibilidad al cambio del MLHF-Q en diseños longitudinales.
Referências
1. Roger VL. Epidemiology of heart failure. Circ Res. 2013; 113(6): 646-659. doi: 10.1161/CIRCRESAHA.113.300268.
2. Ciapponi A, Alcaraz A, Calderon M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin América: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2016; 69(11): 1051-1060. doi: 10.1016/j.rec.2016.04.054.
3. Escobar A, Garcia-Perez L, Navarro G, Bilbao A, Quiros R, group C-HS. A one-year mortality clinical prediction rule for patients with heart failure. Eur J Intern Med. 2017. doi: 10.1016/j.ejim.2017.06.013.
4. Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care. 2010; 4(4): 233-237. doi: 10.1097/SPC.0b013e328340744d.
5. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002; 87(3): 235-241.
6. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012; 125(15): 1928-1952. doi: 10.1161/CIR.0b013e31824f2173.
7. Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999; 16(3): 247-271. doi: 10.2165/00019053-199916030-00003.
8. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992; 124(4): 1017-1025.
9. Lambrinou E, Kalogirou F, Lamnisos D, Middleton N, Sourtzi P, Lemonidou C, et al. Evaluation of the psychometric properties of the Greek version of the Minnesota Living With Heart Failure questionnaire. J Cardiopulm Rehabil Prev. 2013; 33(4): 229-233. doi: 10.1097/HCR.0b013e3182930cbb.
10. Munyombwe T, Hofer S, Fitzsimons D, Thompson DR, Lane D, Smith K, et al. An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. Qual Life Res. 2014; 23(6): 1753-1765. doi: 10.1007/s11136-013-0617-0.
11. Garin O, Soriano N, Ribera A, Ferrer M, Pont A, Alonso J, et al. Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnarie. Rev Esp Cardiol. 2008; 61(3): 251-259.
12. Parajon T, Lupon J, Gonzalez B, Urrutia A, Altimir S, Coll R, et al. Use of the Minnesota Living With Heart Failure Quality of Life Questionnaire in Spain. Rev Esp Cardiol. 2004; 57(2): 155-160.
13. Naveiro-Rilo JC, Diez-Juarez DM, Romero Blanco A, Rebollo-Gutierrez F, Rodriguez-Martinez A, Rodriguez-Garcia MA. Validation of the Minnesota living with heart failure questionnaire in primary care. Rev Esp Cardiol. 2010; 63(12): 1419-1427.
14. Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev. 2014;19(3): 359-367. doi: 10.1007/s10741-013-9394-7.
15. Middel B, Bouma J, de Jongste M, van Sonderen E, Niemeijer MG, Crijns H, et al. Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q). Clin Rehabil. 2001;15(5): 489-500. doi: 10.1191/026921501680425216.
16. Zanolla L, Zardini P. Selection of endpoints for heart failure clinical trials. Eur J Heart Fail. 2003; 5(6): 717-723.
17. Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res. 2009; 18(1): 71-85. doi: 10.1007/s11136-008-9416-4.
18. Saccomann IC, Cintra FA, Gallani MC. Psychometric properties of the Minnesota Living with Heart Failure--Brazilian version--in the elderly. Qual Life Res. 2007; 16(6): 997-1005. doi: 10.1007/s11136-007-9170-z.
19. Ho CC, Clochesy JM, Madigan E, Liu CC. Psychometric evaluation of the Chinese version of the Minnesota Living with Heart Failure Questionnaire. Nurs Res. 2007; 56(6): 441-448. doi: 10.1097/01.NNR.0000299849.21935.c4.
20. Cronbach L. Coefficient alpha and the internal structure of test. Psychometrika. 1951; 16(3): 297-334.
21. Káiser H. An index of factorial simplicity. Psychometrika. 1974; 39: 32-36.
22. Bartlett M. Test of significance in factor analysis. Psychology. 1950; 3: 77-85.
23. Garin O, Ferrer M, Pont A, Wiklund I, Van Ganse E, Vilagut G, et al. Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. Qual Life Res. 2013; 22(10): 2675-2684. doi: 10.1007/s11136-013-0383-z.
24. Bilbao A, Escobar A, Garcia-Perez L, Navarro G, Quiros R. The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes. 2016; 14: 23. doi: 10.1186/s12955-016-0425-7.
25. Tesio L. Measuring behaviours and perceptions: Rasch analysis as a tool for rehabilitation research. J Rehabil Med. 2003; 35(3): 105-115.
26. Mogle J, Buck H, Zambroski C, Alvaro R, Vellone E. Cross-Validation of the Minnesota Living With Heart Failure Questionnaire. J Nurs Scholarsh. 2017; 49(5): 513-520. doi: 10.1111/jnu.12318.
27. Heo S, Moser DK, Riegel B, Hall LA, Christman N. Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire. Nurs Res. 2005; 54(4): 265-272.
28. Moon JR, Jung YY, Jeon ES, Choi JO, Hwang JM, Lee SC. Reliability and validity of the Korean version of the Minnesota Living with Heart Failure Questionnaire. Heart Lung. 2012; 41(1): 57-66. doi: 10.1016/j.hrtlng.2011.09.011.
29. Breidthardt T, Irfan A, Klima T, Drexler B, Balmelli C, Arenja N, et al. Pathophysiology of lower extremity edema in acute heart failure revisited. Am J Med. 2012; 125(11): 1124 e1- e8. doi: 10.1016/j.amjmed.2011.12.015.
30. Kataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013; 36(9): 555-559. doi: 10.1002/clc.22159.
31. Sztajzel J. Chronic heart failure and its consequences on the partner relationship. Rev Med Suisse. 2015; 11(498): 2313-2315.
32. Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010; 3(4): 477-485. doi: 10.1161/CIRCHEARTFAILURE.109.898916.
33. Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012; 5(2): 217-225. doi: 10.1161/CIRCHEARTFAILURE.111.964221.
34. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8): 781-791. doi: 10.1001/jama.2013.905.
2. Ciapponi A, Alcaraz A, Calderon M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin América: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2016; 69(11): 1051-1060. doi: 10.1016/j.rec.2016.04.054.
3. Escobar A, Garcia-Perez L, Navarro G, Bilbao A, Quiros R, group C-HS. A one-year mortality clinical prediction rule for patients with heart failure. Eur J Intern Med. 2017. doi: 10.1016/j.ejim.2017.06.013.
4. Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care. 2010; 4(4): 233-237. doi: 10.1097/SPC.0b013e328340744d.
5. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002; 87(3): 235-241.
6. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012; 125(15): 1928-1952. doi: 10.1161/CIR.0b013e31824f2173.
7. Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999; 16(3): 247-271. doi: 10.2165/00019053-199916030-00003.
8. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992; 124(4): 1017-1025.
9. Lambrinou E, Kalogirou F, Lamnisos D, Middleton N, Sourtzi P, Lemonidou C, et al. Evaluation of the psychometric properties of the Greek version of the Minnesota Living With Heart Failure questionnaire. J Cardiopulm Rehabil Prev. 2013; 33(4): 229-233. doi: 10.1097/HCR.0b013e3182930cbb.
10. Munyombwe T, Hofer S, Fitzsimons D, Thompson DR, Lane D, Smith K, et al. An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. Qual Life Res. 2014; 23(6): 1753-1765. doi: 10.1007/s11136-013-0617-0.
11. Garin O, Soriano N, Ribera A, Ferrer M, Pont A, Alonso J, et al. Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnarie. Rev Esp Cardiol. 2008; 61(3): 251-259.
12. Parajon T, Lupon J, Gonzalez B, Urrutia A, Altimir S, Coll R, et al. Use of the Minnesota Living With Heart Failure Quality of Life Questionnaire in Spain. Rev Esp Cardiol. 2004; 57(2): 155-160.
13. Naveiro-Rilo JC, Diez-Juarez DM, Romero Blanco A, Rebollo-Gutierrez F, Rodriguez-Martinez A, Rodriguez-Garcia MA. Validation of the Minnesota living with heart failure questionnaire in primary care. Rev Esp Cardiol. 2010; 63(12): 1419-1427.
14. Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev. 2014;19(3): 359-367. doi: 10.1007/s10741-013-9394-7.
15. Middel B, Bouma J, de Jongste M, van Sonderen E, Niemeijer MG, Crijns H, et al. Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q). Clin Rehabil. 2001;15(5): 489-500. doi: 10.1191/026921501680425216.
16. Zanolla L, Zardini P. Selection of endpoints for heart failure clinical trials. Eur J Heart Fail. 2003; 5(6): 717-723.
17. Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res. 2009; 18(1): 71-85. doi: 10.1007/s11136-008-9416-4.
18. Saccomann IC, Cintra FA, Gallani MC. Psychometric properties of the Minnesota Living with Heart Failure--Brazilian version--in the elderly. Qual Life Res. 2007; 16(6): 997-1005. doi: 10.1007/s11136-007-9170-z.
19. Ho CC, Clochesy JM, Madigan E, Liu CC. Psychometric evaluation of the Chinese version of the Minnesota Living with Heart Failure Questionnaire. Nurs Res. 2007; 56(6): 441-448. doi: 10.1097/01.NNR.0000299849.21935.c4.
20. Cronbach L. Coefficient alpha and the internal structure of test. Psychometrika. 1951; 16(3): 297-334.
21. Káiser H. An index of factorial simplicity. Psychometrika. 1974; 39: 32-36.
22. Bartlett M. Test of significance in factor analysis. Psychology. 1950; 3: 77-85.
23. Garin O, Ferrer M, Pont A, Wiklund I, Van Ganse E, Vilagut G, et al. Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. Qual Life Res. 2013; 22(10): 2675-2684. doi: 10.1007/s11136-013-0383-z.
24. Bilbao A, Escobar A, Garcia-Perez L, Navarro G, Quiros R. The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes. 2016; 14: 23. doi: 10.1186/s12955-016-0425-7.
25. Tesio L. Measuring behaviours and perceptions: Rasch analysis as a tool for rehabilitation research. J Rehabil Med. 2003; 35(3): 105-115.
26. Mogle J, Buck H, Zambroski C, Alvaro R, Vellone E. Cross-Validation of the Minnesota Living With Heart Failure Questionnaire. J Nurs Scholarsh. 2017; 49(5): 513-520. doi: 10.1111/jnu.12318.
27. Heo S, Moser DK, Riegel B, Hall LA, Christman N. Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire. Nurs Res. 2005; 54(4): 265-272.
28. Moon JR, Jung YY, Jeon ES, Choi JO, Hwang JM, Lee SC. Reliability and validity of the Korean version of the Minnesota Living with Heart Failure Questionnaire. Heart Lung. 2012; 41(1): 57-66. doi: 10.1016/j.hrtlng.2011.09.011.
29. Breidthardt T, Irfan A, Klima T, Drexler B, Balmelli C, Arenja N, et al. Pathophysiology of lower extremity edema in acute heart failure revisited. Am J Med. 2012; 125(11): 1124 e1- e8. doi: 10.1016/j.amjmed.2011.12.015.
30. Kataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013; 36(9): 555-559. doi: 10.1002/clc.22159.
31. Sztajzel J. Chronic heart failure and its consequences on the partner relationship. Rev Med Suisse. 2015; 11(498): 2313-2315.
32. Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010; 3(4): 477-485. doi: 10.1161/CIRCHEARTFAILURE.109.898916.
33. Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012; 5(2): 217-225. doi: 10.1161/CIRCHEARTFAILURE.111.964221.
34. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8): 781-791. doi: 10.1001/jama.2013.905.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Downloads
Não há dados estatísticos.